These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 30689744)

  • 21. Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density.
    Miller PD; Troy S; Weiss RJ; Annett M; Schense J; Williams SA; Mitlak B
    Clin Drug Investig; 2021 Mar; 41(3):277-285. PubMed ID: 33638863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors.
    Cosman F; Hattersley G; Hu MY; Williams GC; Fitzpatrick LA; Black DM
    J Bone Miner Res; 2017 Jan; 32(1):17-23. PubMed ID: 27612281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis.
    Hong P; Liu R; Rai S; Liu J; Zhou Y; Zheng Y; Li J
    J Orthop Surg Res; 2023 Feb; 18(1):116. PubMed ID: 36797767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Safety and Efficacy of Abaloparatide on Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis.
    Xu F; Wang Y; Zhu X
    Clin Ther; 2024 Mar; 46(3):267-274. PubMed ID: 38307725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide.
    Reginster JY; Hattersley G; Williams GC; Hu MY; Fitzpatrick LA; Lewiecki EM
    Calcif Tissue Int; 2018 Nov; 103(5):540-545. PubMed ID: 29951742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abaloparatide Increases Lumbar Spine and Hip BMD in Japanese Patients With Osteoporosis: The Phase 3 ACTIVE-J Study.
    Matsumoto T; Sone T; Soen S; Tanaka S; Yamashita A; Inoue T
    J Clin Endocrinol Metab; 2022 Sep; 107(10):e4222-e4231. PubMed ID: 35977548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy.
    Leder BZ
    Curr Osteoporos Rep; 2017 Apr; 15(2):110-119. PubMed ID: 28303448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial.
    Miller PD; Hattersley G; Lau E; Fitzpatrick LA; Harris AG; Williams GC; Hu MY; Riis BJ; Russo L; Christiansen C
    Bone; 2019 Mar; 120():137-140. PubMed ID: 30359763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial.
    Leder BZ; Zapalowski C; Hu MY; Hattersley G; Lane NE; Singer AJ; Dore RK
    J Bone Miner Res; 2019 Dec; 34(12):2213-2219. PubMed ID: 31411768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.
    Leder BZ; Mitlak B; Hu MY; Hattersley G; Bockman RS
    J Clin Endocrinol Metab; 2020 Mar; 105(3):938-43. PubMed ID: 31674644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New therapeutic targets for osteoporosis.
    Anagnostis P; Gkekas NK; Potoupnis M; Kenanidis E; Tsiridis E; Goulis DG
    Maturitas; 2019 Feb; 120():1-6. PubMed ID: 30583758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial.
    Cosman F; Peterson LR; Towler DA; Mitlak B; Wang Y; Cummings SR
    J Clin Endocrinol Metab; 2020 Nov; 105(11):3384-95. PubMed ID: 32658264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
    J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Abaloparatide: A review of preclinical and clinical studies.
    Brent MB
    Eur J Pharmacol; 2021 Oct; 909():174409. PubMed ID: 34364879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abaloparatide: First Global Approval.
    Shirley M
    Drugs; 2017 Aug; 77(12):1363-1368. PubMed ID: 28624872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abaloparatide dose-dependently increases bone mineral density in postmenopausal women with osteoporosis: a phase 2 study.
    Matsumoto T; Sone T; Yamashita A; Inoue T
    J Bone Miner Metab; 2023 Nov; 41(6):807-816. PubMed ID: 37505256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study.
    Lewiecki EM; Czerwinski E; Recknor C; Strzelecka A; Valenzuela G; Lawrence M; Silverman S; Cardona J; Nattrass SM; Binkley N; Annett M; Pearman L; Mitlak B
    J Bone Miner Res; 2023 Oct; 38(10):1404-1414. PubMed ID: 37417725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when?
    Anastasilakis AD; Yavropoulou MP; Palermo A; Makras P; Paccou J; Tabacco G; Naciu AM; Tsourdi E
    Eur J Endocrinol; 2024 Jul; 191(1):R9-R21. PubMed ID: 38938063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Abaloparatide and the Spine: A Narrative Review.
    Thompson JC; Wanderman N; Anderson PA; Freedman BA
    Clin Interv Aging; 2020; 15():1023-1033. PubMed ID: 32636617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial.
    Bilezikian JP; Hattersley G; Mitlak BH; Hu MY; Fitzpatrick LA; Dabrowski C; Miller PD; Papapoulos SE
    Curr Med Res Opin; 2019 Dec; 35(12):2097-2102. PubMed ID: 31418585
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.